Clinical Trial Update: Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous anti-Bet v 1 monoclonal antibodies showed efficacy in reducing allergic rhinitis and conjunctivitis symptoms and birch ski…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Conjunctivitis

Drugs mentioned

• Anti-Bet v 1 monoclonal antibody (bet v 1-targeted monoclonal antibody)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Allergic Rhinitis, Conjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2024-11-19